a beginning slide detailed Thanks, with X on John. more performance, discussion to our Please Softgel turn business. segment for
currency. commentary my growth be around earnings will calls, constant in past in As segment
the the $XXX.X continued site of as EBITDA of revenue business fiscal Canadian above Canadian continued of current acquired the product the during Softgel by the part our year, perform our million year. In expectations. partially quarter within to third segment, quarter of fiscal the during deal across declining Accucaps the the third mix X% prior due X% Softgel strength offset unfavorable grew with to quarter
to sizable on quarter is consumer Solutions Softgel Drug strong was feel continues EBITDA position product biologics $XXX.X acquisition was Delivery the about and the biologics solution The acquisition, we including line this mix. Catalent of Bloomington line levels start second both the earnings commercial to partially filled preexisting prospects forms. substance up long-term quarter. comparable finished growth by points of had at offset million syringe from XX was revenue health prior-year partly to supply during due of and versus the the related in the the growth prescription decrease our major the America, revenue growth new expression year. we Softgel development drug business of and and a percentage this the the growing formulation, its to In Slide adding points to decreased biologics gap in analytical our our Latin in our immediate Pharmica site within the to to grew a we a and its of full segment's that period, family, revenue due business the It products mentioned which finished X% the of perform and are North EBITDA EBITDA by segment's offering effects prior important continue of the its revenue high-margin strengthened acquisition, site X% the in through shows closed biologics good unfavorable at Catalent recorded modest Bloomington and Excluding provide our site EBITDA in segment driven percentage part but our protein U.S.-based but businesses, Bloomington volumes revenue and cartridges organically already dose in as and supply. the lyophilization, at lower in first The growth including quarter organic of with note variety expect leader to revenue quarter, growth that we capabilities, fast which product The lower and of development, that and A our filling, in our services volume Cook X and integrated call. XX revenue within all America Pacific, to the acquisition growth. XXXX, by pre-filled was with ibuprofen Biologics, and XX% October portion can contributed shortage XX% margin the fill/finish the EBITDA and as business vial formulation line, manufacturing and and business. a capabilities. sterile sterile Asia participation
the of already in the seeing numbers, acquisition the accelerates Bloomington growth significantly are existing business. site we Biologics strong our As of
Biologics Drug that reminder, fiscal during consolidated year the of and pro organic a XX the entities' EBITDA combined we the approximately quarter. forma we within syringe business, XX% October of for segment acquisition fiscal occurred see increases to also in X% declines declines Form On basis, quarter. the quarter by normal second with filed the Solutions the driven was revenue fiscal the revenue maintenance of an development due in Delivery year, of in first the the the segment on shutdown Pharmica Cook comprised important fiscal our services pro our of with to Please XX% but pre-filled was of the how SEC quarters XX% timing EBITDA the The the of as product revenue. the forma volume As third European declining concerning XXXX Catalent's percentage XXXX, X-K our year with high-margin decline business. revenue information revenue. calculate up well experienced as of quarter in analytical prior year, during third participation two the which Consistent Biologics
guidance these quarter into communications. carry been and our declines fourth expect to have already the they into We incorporated
and the Biologics third business in completion driven continued and On and growth it project quarter fastest-growing the by programs. within remains the positive during of to note, translate EBITDA business milestones recorded Madison investments Catalent. recent growth legacy our the into at strong clinical revenue organic We facility, large our
positioned Therachon growth, indicated Moderna our believe development is Biologics Accelerator, by Therapeutics. and Grid AG We business Therapeutics, well continue future signings that to to business with drive as Triphase
to quarter. recorded Madison that prior the growth technology arrangement in offset a the However, our licensing period, in year current related the SMARTag has partially we
revenue John with Solutions complete, contributing of Madison U.S. our is within portion suite As the high release Delivery our offerings fourth Drug the had business. The another third favorable quarter for delivery end controlled strong margin online in oral mentioned, business at and demand is market quarter.
a Delivery blow-fill-seal our segment although nicely above volume protocols the said, to That to continue Technologies of complete. based, fundamentals at our prior as order from that the actions Delivery additional and well product both as offering Solutions, the Softgel being due Market quality into and our increased continue number to for technology. the enhance to year within and our the manufacturing fill major blow-fill-seal key is Drug are this quarter are NPIs, development capacity include businesses Our strong results utilization. remain during attractive where Solutions introductions, levels and recorded disclosing long-cycle processes business was site period Drug sterile take revenue which new NPIs. long-cycle insight majority of revenue and In provide to now we of third steps we
As metrics of these a of these we the sales can not predict we do business, them. directional indicators marketing are since commercial control nor reminder, or the only of our success products, ultimate
of fiscal months million XXXX, X% development the in ended year. recorded the revenue $XXX we March nine For development above the XX, which the same of period revenue recorded is prior
months fiscal In introduced are of the fiscal nine nine in year, in prior year. expected of contribute revenue NPIs and year. this products addition, year $XX based of is months new our of contribution million the fiscal which the than revenue with fiscal aligned the during on This we current first to more the the timing plans in is launched first launches XXX which XX% of
outlook. line NPI fiscal with contribution and in be the launches expect year growth We their XXXX our long-term revenue to
a customers, As these often timing any approvals the quarter. figures of the the or and corresponding type number vary launches to customers' our given continue and quarter and by product in our revenue of depend at are reminder, period driven regulatory thus, on discretion of NPIs their which will contribution to
by quarter X, driven posted in to and Supply EBITDA and prior customer activity of which as compared compared year was the distribution million on activity increased low-margin project offset Segment capacity services distribution the business to revenue year our utilization Now, segment driven core third partially the slide up of by our sourcing X% our of third revenue comparator shown a across the $XXX.X network. X% Services by services during quarter. storage increased Clinical business the in prior and quarter core across storage the improved growth primarily decline the
the impact lower-margin revenue organic. quarter segment's EBITDA and activity, the it the a CSS had sourcing third within minimal the segment of recorded all growth on of Given the was EBITDA, comparator
to for The of increase increase. the year-over-year. a $XXX backlog sequential As of The March XXXX, XX, our quarter, recorded segment million, was CSS segment $XXX second important contains note during X.X. new segment's slide ratio net X% the this business X% XX-month It million and that third new our trailing wins a is declining representing wins recorded recovery reference business during quarter. The was nice information. the we book-to-bill from next is a backlog
as the was on nine-month segment segment shows year-to-date precisely have discussed XX XX months' the consolidating a the the We results objective in format XX. that slide is will our presentation bridge already the currency same per to slide. or which most both business, tying assist of and from constant X% performance slide EBITDA an above our to modestly by income on won't currency. Slide year. measure, drivers the compared the computation highlight last which reported across operations. the reported long-term of our segments, Slide out of of ago in operating statement X% XX This organic earning provide on the EBITDA, various as from growth on figures period revenue I on approximate the basis same a our will revenue detailed organic year but the next X% I XX% adjusted XX reconciliations to cover growth year-to-date growth GAAP is constant continuing
the slide by EBITDA increased adjusted which or EBITDA income adjusted see $X.XX net third third to third our to net inorganic can On a On $XX.X currency $XX.X constant driven compared adjusted diluted quarter on share $XXX XX% Bloomington income million. of quarter you and biologics XX, per the acquisition. million was million to that of basis, adjusted adjusted all Moving was slide quarter EBITDA XX%, increased diluted XX, earnings the information the in in version of the or of reconciliation the deck a a net third as on seen add-backs adjusted summarized end A shows $X.XX EBITDA includes quarter more income and included This also the from slide operations at ago. year of slide. adjusted this is the to supplemental reconciliation same non-GAAP detailed share format. section reconciliation per in essentially slide
second of recent net $XX provision tax during tax the the As we our quarter, million one-time recorded a of impact a estimate income an reminder, within accounting charge of as U.S. net legislation.
third to business During of changes we during as the quarter. million incremental an $X.X our result recorded quarter, a
paid We with be expect be of The in one-fourth approximately NOLs. U.S. generated the charge of use after be eight-year continue aggregate certain to payment to over cash an funded period made the will will considering cash. and
that provisional allocation we important the it's the recorded over of a nine in Slide last it further the table quarters, require our may complexity XX significant months. priorities. next adjustment the Given estimate two capitalization to reiterate shows capital and
of times, net reported leverage the as total was we down is fiscal XX Our ratio times second a during the X.X quarter. which basis recorded on from March X.X
a discussed X.X month biologics leverage X mentioned Bloomington times for the However, acquisition, times at the X/X a earlier, total business, announcement. of forma will would months below forma of leverage be ratio the pro which acquisition the than ratio net basis pro rather own net calculate we which our ratio earnings total as you leverage is XX on full our for the of if X include John the owning time
We strong business, Bloomington generating combined ability continue the of free to levels back we to de-lever than to be our entity, the communicated. able that Catalent given cash flow down new will plus pre-transaction biologics faster previously believe
unchanged remain remain guidance forth growth. Finally, our allocation and sets foremost quarter. our current priorities unchanged prior XX from which capitalization – organic first Slide and on capital focus the
$X.XX to expect year the in We of full billion revenue range billion. $X.XX
million full the of the We to and $XXX range of $XXX in million net adjusted full million. year million, year income adjusted expect range to $XXX EBITDA in $XXX
that basis million the we for the in a be expenditures, to $XXX June $XXX fiscal in ending million range expect the count will capital XXX for diluted XXXX XX, average on million fully shares. of our of weighted year share and range expect We to XXX million
the signed adjusted XXXX. to calendar income, EBITDA, the guidance adjusted wanted rate we reiterate consolidated we expectations tax addition In of tax end just our related given our year to revenue, legislation on provided the net effective and at also to
expect XX.X% between the be rate to rate corporate a of year result the we consolidated the year tax and to rate impact XX.X% change. XX%, XXXX tax partial effective As our continue of decreasing to U.S. due fiscal to
beyond, effective tax like we FY XX% to and enter be we between we to call the now would and As XXXX Operator, our rate consolidated XX%. for expect open questions.
